{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:29:03Z","timestamp":1781929743435,"version":"3.54.5"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biomedical Advanced Research and Development Authority (BARDA)","award":["HHSO100201100013C"],"award-info":[{"award-number":["HHSO100201100013C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Smallpox (variola) virus is considered a Category A bioterrorism agent due to its ability to spread rapidly and the high morbidity and mortality rates associated with infection. Current recommendations recognize the importance of oral antivirals and call for having at least two smallpox antivirals with different mechanisms of action available in the event of a smallpox outbreak. Multiple antivirals are recommended due in large part to the propensity of viruses to become resistant to antiviral therapy, especially monotherapy. Advances in synthetic biology heighten concerns that a bioterror attack with variola would utilize engineered resistance to antivirals and potentially vaccines. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo, has a different mechanism of action from tecovirimat (the only oral smallpox antiviral currently in the US Strategic National Stockpile), and has a resistance profile that reduces concerns in the scenario of a bioterror attack using genetically engineered smallpox. Given the devastating potential of smallpox as a bioweapon, preparation of a multi-pronged defense that accounts for the most obvious bioengineering possibilities is strategically imperative.<\/jats:p>","DOI":"10.3390\/v9110320","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T12:16:23Z","timestamp":1509365783000},"page":"320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak"],"prefix":"10.3390","volume":"9","author":[{"given":"Scott","family":"Foster","sequence":"first","affiliation":[{"name":"Chimerix, Durham, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1079-0988","authenticated-orcid":false,"given":"Scott","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Lanier","sequence":"additional","affiliation":[{"name":"Chimerix, Durham, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon: Medical and public health management","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"key":"ref_2","unstructured":"Gellman, B. (Washington Post, 2001). 4 nations thought to possess smallpox: Iraq, N. Korea named, two officials say, Washington Post."},{"key":"ref_3","unstructured":"Alibek, K., and Handelman, S. (1999). Biohazard: The Chilling True Story of the Largest Biological Weapons Program in the World, Random House."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1126\/science.357.6347.115","article-title":"Labmade smallpox is possible, study shows: Reconstitution of horsepox virus from mail-order DNA reignites synthetic biology debate","volume":"357","author":"Kupferschmidt","year":"2017","journal-title":"Science"},{"key":"ref_5","unstructured":"Arvin, A.M., and Patel, D.M. (2009). Live Variola Virus: Considerations for Continuing Research, The National Academies Press."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"Magee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1128\/AAC.02814-14","article-title":"In vitro efficacy of brincidofovir against variola virus","volume":"58","author":"Olson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/v3010047","article-title":"Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/v3020063","article-title":"Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2015.02.007","article-title":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: A model of smallpox disease","volume":"117","author":"Trost","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2017.04.002","article-title":"Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits","volume":"143","author":"Grossi","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/135965350801300703","article-title":"Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001","volume":"13","author":"Parker","year":"2008","journal-title":"Antivir. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2008.11.015","article-title":"Mousepox in the C57BL\/6 strain provides an improved model for evaluating anti-poxvirus therapies","volume":"385","author":"Parker","year":"2009","journal-title":"Virology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.antiviral.2012.02.005","article-title":"Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox\u2014An animal model of smallpox","volume":"94","author":"Parker","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.antiviral.2017.01.009","article-title":"Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox","volume":"143","author":"Chittick","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jis510","article-title":"Progressive vaccinia: Case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001","volume":"206","author":"Lederman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-016-3534-y","article-title":"Fatal disseminated cowpox virus infection in an adolescent renal transplant recipient","volume":"32","author":"Gazzani","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: Scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","article-title":"RNA virus mutations and fitness for survival","volume":"51","author":"Domingo","year":"1997","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1128\/JVI.00355-12","article-title":"Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus","volume":"86","author":"Duraffour","year":"2012","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1128\/JVI.00605-06","article-title":"Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice","volume":"80","author":"Andrei","year":"2006","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jac\/dku545","article-title":"ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping","volume":"70","author":"Duraffour","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.75.3.1205-1210.2001","article-title":"Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox","volume":"75","author":"Jackson","year":"2001","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2010.10.021","article-title":"Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy","volume":"409","author":"Chen","year":"2011","journal-title":"Virology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/CMR.5.2.146","article-title":"Antiviral therapy: Current concepts and practices","volume":"5","author":"Bean","year":"1992","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_35","unstructured":"(2017, September 11). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Available online: www.aidsinfo.nih.gov\/guidelines."},{"key":"ref_36","unstructured":"(2017, September 11). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online: http:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/HCVGuidance_April_12_2017_b.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/11\/320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:48:51Z","timestamp":1760208531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/11\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"alternative-id":["v9110320"],"URL":"https:\/\/doi.org\/10.3390\/v9110320","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]}}}